Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMPS | P49915 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 6/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311196 | 0.95 | DOT1L (0.34) | GMPSPNMTDOT1LNNMTADORA2A | |
| SCHEMBL21311199 | 0.95 | GMPS (0.35) | GMPSPNMTDOT1LNNMTADORA2A | |
| SCHEMBL21311192 | 0.93 | DOT1L (0.37) | GMPSPNMTDOT1LADORA2AADORA3 | |
| SCHEMBL21311200 | 0.91 | NNMT (0.34) | GMPSPNMTNNMTADORA2AADORA3 | |
| SCHEMBL21311211 | 0.91 | PNMT (0.36) | GMPSPNMTDOT1LNNMTADORA2A | |
| SCHEMBL21311205 | 0.91 | GMPS (0.33) | GMPSDOT1LADORA2AADORA3SLC28A1 | |
| SCHEMBL21311209 | 0.89 | DOT1L (0.38) | GMPSPNMTDOT1L | |
| SCHEMBL21311198 | 0.89 | NNMT (0.34) | GMPSPNMTDOT1LNNMTSLC28A1 | |
| SCHEMBL21311401 | 0.88 | DOT1L (0.36) | GMPSDOT1LADORA2AADORA3SLC28A1 | |
| SCHEMBL21311212 | 0.85 | DOT1L (0.35) | GMPSPNMTDOT1LNNMTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| WO-2018075947-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | GMPS 847/4885PNMT 2859/4885DOT1L 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.